Qin Shijie, Xu Jieyun, Yi Yunmeng, Jiang Sizhu, Jin Ping, Xia Xinyi, Ma Fei
Laboratory for Comparative Genomics and Bioinformatics & Jiangsu Key Laboratory for Biodiversity and Biotechnology, College of Life Science, Nanjing Normal University, Nanjing, China.
Institute of Laboratory Medicine, Jinling Hospital, Nanjing University School of Medicine, The First School of Clinical Medicine, Southern Medical University, Nanjing, China.
Front Oncol. 2021 Jul 1;11:691115. doi: 10.3389/fonc.2021.691115. eCollection 2021.
Many dysregulated microRNAs (miRNAs) have been suggested to serve as oncogenes or tumor suppressors to act as diagnostic and prognostic factors for HCC patients. However, the dysregulated mechanisms of miRNAs in HCC remain largely unknown. Herein, we firstly identify 114 disordered mature miRNAs in HCC, 93 of them are caused by dysregulated transcription factors, and 10 of them are driven by the DNA methylation of their promoter regions. Secondly, we find that seven up-regulated miRNAs (miR-9-5p, miR-452-5p, miR-452-3p, miR-1180-3p, miR-4746-5p, miR-3677-3 and miR-4661-5p) can promote tumorigenesis inhibiting multiple tumor suppressor genes participated in metabolism, which may act as oncogenes, and seven down-regulated miRNAs (miR-99-5p, miR-5589-5p, miR-5589-3p, miR-139-5p, miR-139-3p, miR-101-3p and miR-125b-5p) can suppress abnormal cell proliferation suppressing a number of oncogenes involved in cancer-related pathways, which may serve as tumor suppressors. Thirdly, our findings reveal a mechanism that transcription factor and miRNA interplay can form various regulatory loops to synergistically control the occurrence and development of HCC. Finally, our results demonstrate that this key transcription factor FOXO1 can activate a certain number of tumor suppressor miRNAs to improve the survival of HCC patients, suggesting FOXO1 as an effective therapeutic target for HCC patients. Overall, our study not only reveals the dysregulated mechanisms of miRNAs in HCC, but provides several novel prognostic biomarkers and potential therapeutic targets for HCC patients.
许多失调的微小RNA(miRNA)被认为可作为癌基因或肿瘤抑制因子,充当肝癌患者的诊断和预后因素。然而,miRNA在肝癌中的失调机制仍 largely未知。在此,我们首先在肝癌中鉴定出114个失调的成熟miRNA,其中93个由转录因子失调引起,10个由其启动子区域的DNA甲基化驱动。其次,我们发现7个上调的miRNA(miR-9-5p、miR-452-5p、miR-452-3p、miR-1180-3p、miR-4746-5p、miR-3677-3和miR-4661-5p)可通过抑制参与代谢的多个肿瘤抑制基因促进肿瘤发生,这些miRNA可能充当癌基因,7个下调的miRNA(miR-99-5p、miR-5589-5p、miR-5589-3p、miR-139-5p、miR-139-3p、miR-101-3p和miR-125b-5p)可通过抑制参与癌症相关途径的多个癌基因抑制异常细胞增殖,这些miRNA可能充当肿瘤抑制因子。第三,我们的研究结果揭示了一种机制,即转录因子和miRNA相互作用可形成各种调控环,协同控制肝癌的发生和发展。最后,我们的结果表明,这个关键转录因子FOXO1可激活一定数量的肿瘤抑制miRNA以提高肝癌患者的生存率,提示FOXO1作为肝癌患者的有效治疗靶点。总体而言,我们的研究不仅揭示了miRNA在肝癌中的失调机制,还为肝癌患者提供了几个新的预后生物标志物和潜在治疗靶点。